Vanguard Group Inc. Acquires 37,197 Shares of Labcorp Holdings Inc. $LH

Vanguard Group Inc. boosted its holdings in Labcorp Holdings Inc. (NYSE:LH) by 0.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 9,850,631 shares of the medical research company’s stock after buying an additional 37,197 shares during the quarter. Vanguard Group Inc. owned 0.12% of Labcorp worth $2,471,326,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Victory Capital Management Inc. increased its stake in Labcorp by 20.0% in the 3rd quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock worth $756,878,000 after acquiring an additional 440,224 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Labcorp by 10.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,204,276 shares of the medical research company’s stock worth $554,728,000 after acquiring an additional 207,962 shares during the last quarter. Wellington Management Group LLP increased its stake in Labcorp by 15.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after acquiring an additional 289,029 shares during the last quarter. Bank of America Corp DE increased its position in shares of Labcorp by 4.0% during the 3rd quarter. Bank of America Corp DE now owns 726,090 shares of the medical research company’s stock valued at $208,431,000 after purchasing an additional 27,879 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of Labcorp by 2.0% during the 3rd quarter. Legal & General Group Plc now owns 689,581 shares of the medical research company’s stock valued at $197,951,000 after purchasing an additional 13,423 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on LH shares. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Piper Sandler increased their price objective on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. increased their price objective on Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $307.20.

Labcorp Price Performance

Shares of LH stock opened at $257.38 on Thursday. The firm has a market cap of $21.15 billion, a P/E ratio of 24.61, a P/E/G ratio of 1.80 and a beta of 1.02. Labcorp Holdings Inc. has a fifty-two week low of $234.15 and a fifty-two week high of $293.72. The business’s 50 day moving average price is $271.20 and its 200-day moving average price is $267.56. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. The firm had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, equities research analysts anticipate that Labcorp Holdings Inc. will post 17.67 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. Labcorp’s payout ratio is presently 27.53%.

Insider Buying and Selling

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of Labcorp stock in a transaction on Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the transaction, the executive vice president owned 2,579 shares in the company, valued at approximately $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the transaction, the executive vice president owned 2,782 shares of the company’s stock, valued at $807,948.44. This represents a 3.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,113 shares of company stock worth $4,547,450 over the last three months. 0.84% of the stock is owned by corporate insiders.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.